1 Guidance

1.1 Sofosbuvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1.

Table 1 Sofosbuvir for treating adults with chronic hepatitis C

	Sofosbuvir in combination with peginterferon alfa and ribavirin		Sofosbuvir in combination with ribavirin
Genotype	Treatment history	Recommendation	Treatment history	Recommendation
Adults with genotype 1 HCV	All	Recommended	All	Not recommended
Adults with genotype 2 HCV	All	Not licensed for this population	Treatment-naive	Only recommended for people who are intolerant to or ineligible for interferon
Adults with genotype 2 HCV	All	Not licensed for this population	Treatment-experienced	Recommended
Adults with genotype 3 HCV	Treatment-naive	Only recommended for people with cirrhosis	Treatment-naive	Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon
Adults with genotype 3 HCV	Treatment-experienced	Recommended	Treatment-experienced	Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon
Adults with genotype 4, 5 or 6 HCV	All	Only recommended for people with cirrhosis	All	Not recommended
HCV – hepatitis C virus Treatment‑naive – the person has not had treatment for chronic hepatitis C Treatment‑experienced – the person's hepatitis C has not adequately responded to interferon‑based treatment

1.2 People currently receiving treatment initiated within the NHS with sofosbuvir that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.